Board summary
Key figures
39,315
Registered population
63.5% aged 18–64
11.2%
Aged 65+
ICB 19.9% · England 17.9%
17.1%
Ethnic minority (non-White)
6.2% Asian · England 9.6%
29.4%
In IMD quintile 1
ICB 17.1% · England 21.0%
~11,056
Core20 residents (est.)
Resident basis; registered basis ~11,624 · see page 3
4,646
Hypertension register
+8.04% in 3 yrs · England +5.60%
379
SMI register
13.3% of Medway (LAD)'s
563
COPD register
Reviews -6.76% in 3 yrs
Forecast to 2030
6,211
Hypertension patients, 2030
+1,565 on today
78.6%
QRISK ≥20% on statins, 2030
+5.22pp over 3 yrs
3.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Age-five MMR2 uptake lags target by 28.6 pp.
Age-5 MMR2 coverage is 66.4% (England 82.8%), with a 25.2 pp dose drop at Princes Park Medical Ctr versus 8.3 pp at Maidstone Road.
Asthma review coverage falls behind England.
Asthma annual review coverage is 59.2% (England 65.7%) after falling 4.6% over three years (England +4.4%), leaving about 750 patients without a recorded review.
Rapid three-year gains in diabetes and heart failure.
Non-frail diabetes HbA1c control rose +23.1% (England +4.4%) to 48.0% (England 57.4%), while heart failure functional reviews rose +69.9% (England +8.7%).
Population, age and ethnicity
Aged 0-17 patients reach 25.3%, exceeding Medway, ICB, and England proportions
Across 39,315 registered patients, MPA PCN has a younger profile: 25.3% (9,962 patients) are aged 0-17, exceeding Medway (21.6%), NHS Kent and Medway ICB (20.7%), and England (19.6%). Patients aged 65+ comprise 11.2% (4,391), below Medway (17.9%), the ICB (19.9%), and England (17.9%). Princes Park Medical Ctr has 26.1% aged 0-17, whereas Maidstone Road Surgery has 15.5% aged 65+. Census resident figures show an 82.9% White share (Medway 84.3%, ICB 88.6%, England 81.1%) and a 17.1% ethnic minority share, though resident data does not record registered-patient ethnicity.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Medway (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Medway LA) | 1,507 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 74.3% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 48.0% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Medway LA) | 740 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Medway LA) | 19.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 29.4% of patients, concentrated at Princes Park Medical Ctr
Across MPA PCN, 29.4% of registered patients live in Core20 communities, above Medway (23.1%), NHS Kent and Medway ICB (17.1%) and England (21.0%), with an average IMD decile of 4.3 (Medway 4.9, ICB 5.4, England 5.5). Modelled weighted practice shares (29.6%) show a 0.19 pp reconciliation gap against the PCN rate. Core20 concentration reaches 33.7% at Princes Park Medical Ctr (an estimated 10,281 patients) versus 15.3% at Maidstone Road Surgery (an estimated 1,343 patients), an 18.4 pp spread. Clinical and proactive outreach capacity should focus on Princes Park Medical Ctr.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
379
SMI register
0.98% recorded prevalence
379
Learning disability register
0.98% recorded prevalence
47
Care homes, 1,267 beds
In the PCN catchment
8.9%
Provide unpaid care
Medway (LAD), Census 2021
The PCN records 379 patients on the learning disability register (1.0%), above Medway (0.7%), NHS Kent and Medway ICB (0.6%), and England (0.6%), alongside 379 severe mental illness patients (1.0%; England 1.0%). Catchment data shows 47 care homes with 1,267 beds, which does not confirm resident patient numbers. Learning disability prevalence exceeds all benchmarks, so completing tailored annual health checks is the priority workload to protect.
Severe mental illness: physical health checks
Annual BMI recording for severe mental illness patients fell 10.0 pp over 2023 to 2025 (England +5.1 pp) to 78.5% (England 82.1%), while blood pressure checks rose 8.6 pp (England +4.4 pp) to 76.7% (England 83.4%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,646
Hypertension register
+8.04%
Register growth, 3 yrs
Medway (LAD) +3.74% · England +5.60%
+4.60pp
BP control, under 80
≤140/90 · +5.91pp aged 80+
+1,565
More patients by 2030
Forecast 6,211 (13.97%)
Hypertension case-finding and control
Hypertension prevalence is 12.0% (4,646 patients), below Medway (15.4%) and England (15.2%), giving an unadjusted scenario gap of +1,342 to +1,428 patients that may be an upper bound given the younger population (11.2% aged 65+ vs 17.9% in England). While under-80 blood pressure control rose +8.0% over 2023 to 2025 (England +3.2%), current control is 62.1% against 67.8% in England, with Princes Park Medical Ctr at 60.0% and Maidstone Road Surgery at 68.0%. Lagging blood pressure control among patients under 80 leaves an identifiable gap against national benchmarks, indicating that titration and recall could be prioritised at Princes Park Medical Ctr.
Lipids and statins
Uptake of lipid-modifying therapy in high-risk patients (QRISK ≥ 20%) is 66.8%, exceeding Medway (64.0%) and England (63.6%). In CKD, coverage reaches 72.9% (England 70.3%). Higher coverage than national benchmarks indicates that sustaining treatment adherence across high-risk primary prevention cohorts remains the clinical priority.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 50,000 | £2.30 | £1.90 | £1.86 | £115,000 |
| Cardiovascular (all), 2025 | 62,046 | £3.01 | £3.57 | £3.33 | £186,758 |
In 2026, the PCN prescribed 50,000 lipid-modifying items at £2.30 per item, compared to £1.86 in England, £1.87 in Medway, and £1.90 across the ICB, spending £22,000 more than at England's unit cost. Spending more per item than England points to an opportunity for clinical pharmacists to review lipid-modifying prescribing choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−4.61%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.31%
Asthma prevalence, PCN 3-yr % change
Asthma annual review coverage is 59.2% (Medway 62.6%, England 65.7%), following a 4.6% decline over 2023 to 2025 (England +4.4%), leaving about 750 patients unreviewed. COPD reviews fell 6.8% over 2023 to 2025 (England +2.8%) to 75.1% (England 76.4%), while COPD prevalence fell 12.0% (England +2.6%) to 1.4% (England 1.9%). Asthma management items prescribed for ages 5-19 stand at 1,062 per 1,000 (England 1,488).
Cancer register and children's immunisation
Cancer register prevalence is 2.7% (England 3.8%). In Q1 2025/26, age-5 MMR dose 2 and 4-in-1 coverage are both 66.4%, below the 95.0% target by 28.6 pp (England 82.8% and 80.9%). The PCN MMR first-to-second dose drop is 21 pp (from 87.4%), reaching 25.2 pp at Princes Park Medical Ctr against 8.3 pp at Maidstone Road Surgery.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022 across NHS Kent and Medway ICB, 55.6% of staged cancers were diagnosed at stage 1 or 2 (4,661 of 8,384 staged cancers; distance -19.4 pp to the 75.0% national ambition; England 55.3%), with known stage recorded for 63.6% of 13,189 registrations; reaching the ambition requires about 1,630 extra early diagnoses annually. At PCN level, cervical screening uptake is 62.8% (Medway LAD 71.5%, England 66.8%) and breast screening coverage is 62.3% (Medway LAD 69.2%, England 69.9%). Princes Park Medical Ctr records 61.2% in cervical screening, while Maidstone Road Surgery records 69.0%. Crude cancer prevalence is 2.7% (1,059 patients; England 3.8%), which is not age-adjusted.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Medway NHS Foundation Trust achieved 81.6% against the 85.0% cancer 62-day standard (distance -3.4 pp; ICB 75.9%, England 71.2%, Maidstone and Tunbridge Wells NHS Trust 87.4%). It met the 28-day faster diagnosis standard at 77.8% (standard 75.0%; ICB 76.8%, England 79.3%) and the 31-day standard at 99.6% (standard 96.0%). For diagnostics, 14.2% of patients waited 6+ weeks across all diagnostic tests (England 23.1%, Maidstone and Tunbridge Wells NHS Trust 6.4%), including 1.9% for colonoscopy (England 30.8%) but 36.6% for echocardiography (England 28.5%). These provider figures describe system access, not PCN performance.
| Pathways within standard (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.77 | 81.78 | 67.45 | 76.78 | 79.32 |
| 31-day treatment (96%) | 99.62 | 98.35 | 81.88 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 81.64 | 87.43 | 50.25 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | England |
|---|---|---|---|---|
| MRI | 0.68 | 0.92 | 23.35 | 21.40 |
| CT | 0.00 | 0.51 | 6.07 | 9.92 |
| Echocardiography | 36.62 | 2.57 | 65.05 | 28.48 |
| Colonoscopy | 1.88 | 19.80 | 64.09 | 30.83 |
| Gastroscopy | 3.32 | 24.03 | 59.76 | 29.02 |
| All 15 DM01 tests | 14.20 | 6.42 | 41.54 | 23.14 |
| Community services activity | Medway residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 43,510 | 254,055 |
| Referrals | 8,580 | 68,085 |
| Patients with a contact | 11,540 | 72,060 |
Community services (residents of Medway), Jun 2026 (provisional). In June 2026, provisional community services records showed 43,510 care contacts across 11,540 Medway residents, with 8,580 referrals and 31,250 care activities; adults aged 65+ accounted for 62% of contacts (26,985). Across NHS Kent and Medway ICB, contacts totaled 254,055 across 72,060 patients, with 68,085 referrals. These experimental provider submissions reflect wider system community activity rather than exclusive PCN caseloads.
Practice variation and patient experience
Phone access is 31.8% to 34.6% across practices, trailing England's 56.9% benchmark
In 2025/26, QOF clinical-domain achievement was 97.9% at Maidstone Road Surgery and 96.4% at Princes Park Medical Ctr (England 97.1%). In the vaccination and immunisation domain, achievement was 24.8% and 18.5% respectively (England 55.2%, a 6.3 pp spread). Personalised care adjustment rates across all domains were 12.6% at Maidstone Road Surgery and 14.3% at Princes Park Medical Ctr (England 10.0%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Princes Park | 136 | 33.7 | 31.8% | 48.0% | 53.6% |
| Maidstone Road | 100 | 15.3 | 34.6% | 56.3% | 52.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Severe mental illness BMI checks and respiratory reviews lagged national growth over three years
Over three years, the PCN lagged national trends most sharply in annual BMI recording for mental health patients over 2023 to 2025, falling 10.0 pp (England +5.1 pp). Recorded prevalence fell 12.0% for COPD (England +2.6%) and 8.0% for learning disability (England +5.4%), while annual reviews fell 6.8% for COPD (England +2.8%) and 4.6% for asthma (England +4.4%). Conversely, three-year relative growth exceeded England for heart failure reviews (+69.9% vs +8.7%), non-frail diabetes control (+23.1% vs +4.4%), and breast screening over 2023 to 2024 (+22.9% vs +8.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BMI record (SMI)
COPD register
Learning disability register
COPD reviews
Asthma reviews
Heart failure reviews
Diabetes HbA1c control
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Medway (LAD) | Asset | PCN | Medway (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 47 (1,267 beds) | n/a | Schools (catchment) | 114 | n/a |
| Children's centres | 8 | 19 | Places of worship | 56 | 110 |
| Libraries | 3 | 9 | Food banks (VCS) | 2 | 6 |
| Homelessness support (VCS) | 1 | 9 | Day centres (VCS) | 8 | 29 |
| Children and young people (VCS) | 29 | 65 | Carers support groups (VCS) | 10 | 22 |
| Primary schools (LA maintained) | 9 | 17 | Primary academies | 27 | 56 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Age-five immunisation recall in Core20
Age-5 MMR2 and 4-in-1 coverage are both 66.4% in Q1 2025/26 (cohort 143; England 82.8% and 80.9%), below the 95.0% target by 28.6 pp, with a 21 pp drop from MMR1 (87.4%). For discussion, audit age-5 call-recall lists, verify contact details for non-responders, and test flexible pre-school vaccination slots. Moderate effort to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Structured asthma and COPD review recall
Asthma reviews are 59.2% (England 65.7%, Medway 62.6%), leaving 751 (about 750) of 1,843 patients unreviewed; COPD reviews fell 6.8% over 2023 to 2025 (England +2.8%) to 75.1%. For discussion, practices could run a single respiratory recall template, align inhaler checks with annual reviews, and offer flexible slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Hypertension case-finding and under-80 BP titration
Under-80 BP control is 62.1% (England 67.8%, Medway 65.3%; Princes Park Medical Ctr 60.0%). Hypertension prevalence is 12.0% (4,646 patients; England 15.2%, Medway 15.4%), an unadjusted gap of +1,342 to +1,428. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric capacity and outreach planning (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Targeted Core20 proactive outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI cardiometabolic check review (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and digital triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Age-five immunisation recall in Core20 (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target · Core20PLUS5 · 10YHP equity test | PCN & Practice |
| Option 2 · Structured asthma and COPD review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN & Practice |
| Option 3 · Hypertension case-finding and under-80 BP titration (p12) | Hypertension register · Hypertension: QOF prevalence · Registered population | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
